CELL INTELLIGENCE · 肿瘤细胞治疗研究

突变型 p53 通过抑制 SPP1 使 KRAS 驱动的肺腺癌对免疫治疗敏感

Mutant p53 sensitizes KRAS-driven lung adenocarcinoma to immunotherapy by repressing SPP1.

癌症中的 B 细胞：功能、机制与治疗进展

B cells in cancer: functions, mechanisms and therapeutic advances.

既往有口腔扁平苔藓的患者从 PD-1 转换为 PD-L1 后泛发性皮肤扁平苔藓复发：一例病例报告

Recurrence of generalized cutaneous lichen planus after switching from PD-1 to PD-L1 in a patient with pre-existing oral lichen planus: a case report.

RAD001 佐剂流感疫苗与抗程序性细胞死亡蛋白 1 治疗协同增强程序性细胞死亡配体 1 低表达小鼠肺癌的抗肿瘤免疫

RAD001-Adjuvanted Influenza Vaccine Synergizes With Anti-Programmed Cell Death Protein 1 Therapy to Enhance Antitumor Immunity in Programmed Cell Deat

RAD001 佐剂流感疫苗接种通过促进促炎免疫微环境，安全增强了抗 PD-1 疗法在 PD-L1 低表达小鼠肺癌中的疗效。这些发现表明，策略性疫苗佐剂选择可以拓宽免疫检查点抑制剂的治疗范围。

肺腺癌患者 PD-1 抑制剂（替雷利珠单抗）治疗后 CASPR2 抗体相关神经系统综合征：病例报告与文献综述

CASPR2 antibody-associated neurological syndrome after PD-1 inhibitor treatment (tislelizumab) in a patient with lung adenocarcinoma: A case report an

硒作为免疫调节辅助剂增强非小细胞肺癌抗 PD-1 治疗的疗效

Selenium serves as an immunomodulator adjunct to enhance the efficacy of anti-PD-1 therapy in non-small cell lung cancer.

胸腺肽α-1 在肿瘤治疗中的作用：免疫调节机制、临床应用及转化前景

Thymosin α-1 in cancer therapy: Immunomodulatory mechanisms, clinical applications, and translational perspectives.

iPSC 来源 CAR-NK 细胞外囊泡治疗非小细胞肺癌：证据、工程化改造与转化障碍

iPSC-derived CAR-NK extracellular vesicles for non-small cell lung cancer: evidence, engineering, and translational barriers.

中药注射剂联合化疗治疗晚期非小细胞肺癌的疗效和安全性比较：一项贝叶斯网络 meta 分析

Comparative efficacy and safety of traditional Chinese medicine injections combined with chemotherapy for advanced non-small cell lung cancer: a Bayes

TCMIs 联合化疗可能与晚期 NSCLC 患者临床反应、免疫相关指标、肿瘤相关标志物及治疗耐受性的改善相关。然而，鉴于证据确定性有限、异质性较大以及纳入研究的方法学局限性，这些发现应谨慎解读，并需通过高质量的前瞻性研究加以证实。

实体瘤与血液系统恶性肿瘤中的肿瘤免疫治疗：进展、挑战与实践框架

Tumour immunotherapy in solid and hematologic malignancies: Progress, challenges, and a practical framework.